Laura I. Bushnell - 23 May 2024 Form 4 Insider Report for Vincerx Pharma, Inc. (VINC)

Reporting relationship: Director
Issuer ticker: VINC
Reported as of: 23 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2024, 16:35:47 UTC
Prior SEC filing: 30 May 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Laura I. Bushnell

Key filing fact

Laura I. Bushnell filed Form 4 for Vincerx Pharma, Inc. (VINC) on 28 May 2024.

Key facts

This page summarizes Laura I. Bushnell's Form 4 filing for Vincerx Pharma, Inc. (VINC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 May 2024, 16:35.

Change

Previous filing in this sequence was filed on 30 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VINC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 23 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.7036
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full on the earlier of May 23, 2025, the next annual meeting of stockholders, or the consummation of a change of control, subject to the director's continued service.